EUVIMEDOpdag EUVIMED
EvaluationsstudieOpen access

Quantitative evaluation of 90 Y‐PET/CT and 90 Y‐SPECT/CT‐based dosimetry following Yttrium‐90 radioembolization

Srinivas Cheenu Kappadath, Eric Courtney Henry, Benjamin P Lopez, Armeen Mahvash

Medical Physics · 2024-09 · 51 (9) · 6061-6074

DOI: 10.1002/mp.17175 ↗

At a glance

Evaluationsstudie in Medical Physics, published online on 2024-05-23. Written by Srinivas Cheenu Kappadath and 3 co-authors. Institution: Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Major MEDLINE topics: Yttrium Radioisotopes, Positron Emission Tomography Computed Tomography, Embolization, Therapeutic, Radiometry. Cited 12 times so far (Crossref); 44 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, University of Texas MD Anderson Cancer Center, NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Following yttrium‐90 radioembolization ( 90 Y‐RE), 90 Y‐PET/CT and 90 Y‐SPECT/CT imaging provide the means to calculate the voxelized absorbed dose distribution. Given the widespread use of the two imaging modalities and lack of well‐established standardized dosimetry protocols for 90 Y‐RE, there is a clinical need to systematically investigate and evaluate differences in the performance of voxel‐based dosimetry between 90 Y‐PET/CT and 90 Y‐SPECT/CT.

Purpose

To quantitatively analyze and compare 90 Y‐PET/CT and 90 Y‐SPECT/CT‐based dosimetry following 90 Y‐RE.

Methods

90 Y‐PET/CT and 90 Y‐SPECT/CT imaging was acquired for 35 patients following 90 Y‐RE with TheraSphere for the treatment of unresectable hepatocellular carcinoma. Dosimetry was performed using the local deposition method with known activity and the mean dose ( D mean ) was calculated for perfused liver volumes (PV), tumors (T), and perfused normal livers (NL). Additionally, the absorbed dose to x% of the volume ( D x , x [5%, 10%, …, 90%, 95%]) and the volume receiving y Gy ( V y , y [10 Gy, 20 Gy, …, 190 Gy, 200 Gy]) were calculated for T and NL, respectively. Dose metrics were compared using linear regression, Bland‐Altman analysis, and statistical testing.

Results

Both 90 Y‐SPECT/CT and 90 Y‐PET/CT‐based tumor D mean were strongly correlated ( R 2 ≥ 0.90) with D x , excluding metrics on the extrema. Intra‐modality comparisons of various D x and V y metrics yielded statistically significant differences (ANOVA, p < 0.001) for both 90 Y‐PET/CT and 90 Y‐SPECT/CT. Based on statistical testing, only D x metrics separated by greater than 20%–30% coverage, and only V y metrics separated by greater than 40–70 Gy, reported significant differences. For PV, there was a strong correlation ( R 2 ≥ 0.99) between D mean derived separately from 90 Y‐PET/CT and 90 Y‐SPECT/CT imaging. The strength of the correlation was slightly reduced for T and NL with R 2 = 0.91 and R 2 = 0.95, respectively. For PV, the mean bias ± standard error (SE) and 95% limits of agreement (LOA) between D mean from the two modalities was effectively zero with ‐0.8 ± 0.4% (± 2.5%). For T and NL, the mean bias ± SE (± LOA) was ‐14.5 ± 3.7% (± 24%) and 9.4 ± 4.7% (± 27%), respectively.

Conclusion

The strong correlation between D mean and D x suggests information from multiple dose metrics (e.g., D 70 and D mean ) is largely redundant when establishing dose‐response relationships in 90 Y‐RE. D mean is highly correlated between 90 Y‐PET/CT and 90 Y‐SPECT/CT‐based dosimetry, for all liver VOIs. Relative to 90 Y‐SPECT/CT, 90 Y‐PET/CT, on average, yielded higher D mean to tumors (14%) and lower D mean to perfused normal livers (9%). Absorbed dose differences for perfused liver volumes between 90 Y‐SPECT/CT and 90 Y‐PET/CT were negligible.

Subjects

MeSH terms (MEDLINE)

Yttrium RadioisotopesPositron Emission Tomography Computed TomographyEmbolization, TherapeuticRadiometryLiver NeoplasmsHumansMaleFemaleCarcinoma, HepatocellularMiddle AgedAgedSingle Photon Emission Computed Tomography Computed Tomography

Author keywords

PETSIRTSPECTdosimetryradioembolizationyttrium‐90

Substances

Yttrium RadioisotopesYttrium-90

Authors and institutions

  • Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Funding

  • NCI NIH HHS
  • University of Texas MD Anderson Cancer Center
  • NIH HHS
  • Boston Scientific
  • Boston Scientific Corporation
  • National Institutes of Health

Cite

APA

Kappadath, S. C., Henry, E. C., Lopez, B. P., & Mahvash, A. (2024). Quantitative evaluation of 90 Y‐PET/CT and 90 Y‐SPECT/CT‐based dosimetry following Yttrium‐90 radioembolization. Medical Physics, 51(9), 6061-6074. https://doi.org/10.1002/mp.17175

Vancouver

Kappadath SC, Henry EC, Lopez BP, Mahvash A. Quantitative evaluation of 90 Y‐PET/CT and 90 Y‐SPECT/CT‐based dosimetry following Yttrium‐90 radioembolization. Medical Physics. 2024;51(9):6061-6074. doi:10.1002/mp.17175

BibTeX
@article{Kappadath2024,
  author = {Kappadath, Srinivas Cheenu and Henry, Eric Courtney and Lopez, Benjamin P and Mahvash, Armeen},
  title = {Quantitative evaluation of 90 Y‐PET/CT and 90 Y‐SPECT/CT‐based dosimetry following Yttrium‐90 radioembolization},
  journal = {Medical Physics},
  year = {2024},
  volume = {51},
  number = {9},
  pages = {6061--6074},
  doi = {10.1002/mp.17175}
}
Start for free →